Washout periods for brimonidine 0.2% and latanoprost 0.005%.
OBJECTIVE
To evaluate the intraocular pressure washout time after discontinuing brimonidine 0.2% twice daily and latanoprost 0.005% once every evening.


METHODS
We discontinued brimonidine or latanoprost in a masked fashion from primary open-angle glaucoma or ocular hypertensive patients. The intraocular pressure was measured twice weekly until patients returned to untreated baseline.


RESULTS
In 32 patients, the mean longest eye washout time for brimonidine (n = 15) was 3.3 +/- 3.0 weeks and for latanoprost (n = 17) was 4.4 +/- 3.2 weeks (P =.24). In all but one patient, brimonidine returned to baseline by 5 weeks and latanoprost returned by 8 weeks.


CONCLUSIONS
After discontinuing latanoprost or brimonidine, a wide variation exists in washout times among individuals, with latanoprost demonstrating a trend to a longer washout period.
Stewart
W C
WC
Pharmaceutical Research Corporation, Charleston, South Carolina 29412-2646, USA. pr_adm@bellsouth.net
Holmes
K T
KT
Johnson
M A
MA
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000368:Aged; D000068438:Brimonidine Tartrate; D005260:Female; D005902:Glaucoma, Open-Angle / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000378:metabolism / Q000503:physiopathology; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D011810:Quinoxalines / Q000627:therapeutic use*; D016037:Single-Blind Method; D013997:Time Factors
D000316:Adrenergic alpha-Agonists; D011461:Prostaglandins F, Synthetic; D011810:Quinoxalines; D000068438:Brimonidine Tartrate; D000077338:Latanoprost